D'Aloja P, Olivetta E, Bona R, Nappi F, Pedacchia D, Pugliese K, Ferrari G, Verani P, Federico M
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
J Virol. 1998 May;72(5):4308-19. doi: 10.1128/JVI.72.5.4308-4319.1998.
We previously demonstrated that expression of the nonproducer F12-human immunodeficiency virus type 1 (HIV-1) variant induces a block in the replication of superinfecting HIV that does not depend on the down-regulation of CD4 HIV receptors. In order to individuate the gene(s) involved in F12-HIV-induced interference, vectors expressing each of the nine F12-HIV proteins were transfected in HIV-susceptible HeLa CD4 cells. Pools of cell clones stably producing each viral protein were infected with HIV-1, and virus release was measured in terms of reverse transcriptase activity in supernatants. We hereby demonstrate that HeLa CD4 cells expressing the F12-HIV gag, vif, or nef gene were resistant, to different degrees, to infection with T-cell-line-adapted HIV-1 strains. Conversely, expression of either the tat, rev, or vpu F12-HIV gene increased the rate of HIV release, and no apparent effects on HIV replication were observed in cells expressing either the F12-HIV vpr, pol, or env gene. No variation of CD4 exposure was detected in any of the uninfected HeLa CD4 pools. These data indicate that F12-HIV homologous viral interference is the consequence of the synergistic anti-HIV effects of Gag, Vif, and Nef proteins. Retrovirus vectors expressing F12-HIV vif or nef allowed us to further establish that the expression of each mutated protein (i) inhibits the replication of clinical HIV-1 isolates as well, (ii) impairs the infectivity of the virus released by cells chronically infected with HIV-1, and (iii) limitedly to F12-HIV Vif protein, induces HIV resistance in both vif-permissive and vif-nonpermissive cells. The levels of action of F12-HIV vif and nef anti-HIV effects were also determined. We observed that HIV virions emerging from the first viral cycle on F12-HIV vif-expressing cells, although released in unaltered amounts, had a strongly reduced ability to initiate the retrotranscription process when they reinfected parental HeLa CD4 cells. Differently, we observed that expression of F12-HIV Nef protein affects the HIV life cycle at the level of viral assembling and/or release. For the first time, an inhibitory effect on the HIV life cycle in both acutely and chronically infected cells induced by mutated Vif and Nef HIV-1 proteins is described. These genes could thus be proposed as new useful reagents for anti-HIV gene therapy.
我们之前证明,非产生性F12 - 1型人类免疫缺陷病毒(HIV - 1)变体的表达会诱导对超感染HIV复制的阻滞,这并不依赖于CD4 HIV受体的下调。为了确定参与F12 - HIV诱导干扰的基因,将表达九种F12 - HIV蛋白中每一种的载体转染到对HIV敏感的HeLa CD4细胞中。用HIV - 1感染稳定产生每种病毒蛋白的细胞克隆池,并根据上清液中的逆转录酶活性来测量病毒释放。我们在此证明,表达F12 - HIV gag、vif或nef基因的HeLa CD4细胞对T细胞系适应的HIV - 1毒株感染具有不同程度的抗性。相反,表达tat、rev或vpu F12 - HIV基因会增加HIV的释放速率,并且在表达F12 - HIV vpr、pol或env基因的细胞中未观察到对HIV复制有明显影响。在任何未感染的HeLa CD4细胞池中均未检测到CD4暴露的变化。这些数据表明,F12 - HIV同源病毒干扰是Gag、Vif和Nef蛋白协同抗HIV作用的结果。表达F12 - HIV vif或nef的逆转录病毒载体使我们能够进一步确定,每种突变蛋白的表达(i)也抑制临床HIV - 1分离株的复制,(ii)损害慢性感染HIV - 1的细胞释放的病毒的感染性,以及(iii)仅限于F12 - HIV Vif蛋白,在vif允许和vif不允许的细胞中均诱导HIV抗性。还确定了F12 - HIV vif和nef抗HIV作用的作用水平。我们观察到,从表达F12 - HIV vif的细胞上的第一个病毒周期产生的HIV病毒颗粒,尽管释放量未改变,但当它们重新感染亲本HeLa CD4细胞时,启动逆转录过程的能力大大降低。不同的是,我们观察到F12 - HIV Nef蛋白的表达在病毒组装和/或释放水平上影响HIV生命周期。首次描述了由突变的Vif和Nef HIV - 1蛋白在急性和慢性感染细胞中对HIV生命周期的抑制作用。因此,这些基因可被提议作为抗HIV基因治疗的新的有用试剂。